Exscientia (EXAI) Stock Price, News & Analysis

Company Overview

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Key Stats

• Today's Range: $4.84 to $4.84
• 50-Day Range: $4.58 to $5.96
• 52-Week Range: $3.80 to $7.91
• Volume: N/A
• Average Volume: 828,776 shs
• Market Capitalization: $632.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Hold

Exscientia Stock Analysis - MarketRank™

Exscientia scored higher than 45% of companies evaluated by MarketBeat, and ranked 666th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Exscientia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Exscientia has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Exscientia are expected to grow in the coming year, from ($1.25) to ($1.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exscientia is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exscientia is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exscientia has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.55% of the float of Exscientia has been sold short.

Short Interest Ratio / Days to Cover

Exscientia has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Exscientia has recently decreased by 3.77%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exscientia does not currently pay a dividend.

Dividend Growth

Exscientia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.55% of the float of Exscientia has been sold short.

Short Interest Ratio / Days to Cover

Exscientia has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Exscientia has recently decreased by 3.77%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.34

News Sentiment

Exscientia has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Exscientia this week, compared to 5 articles on an average week.

Search Interest

12 people have searched for EXAI on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.

MarketBeat Follows

16 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Exscientia insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EXAI Stock Analysis - Frequently Asked Questions

How have EXAI shares performed this year?

Exscientia's stock was trading at $6.41 at the beginning of 2024. Since then, EXAI stock has decreased by 24.5% and is now trading at $4.84.
View the best growth stocks for 2024 here.

How were Exscientia's earnings last quarter?

Exscientia plc (NASDAQ:EXAI) announced its earnings results on Thursday, August, 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.05. The company earned $5.60 million during the quarter. Exscientia had a negative net margin of 882.09% and a negative trailing twelve-month return on equity of 49.10%.

When did Exscientia IPO?

Exscientia (EXAI) raised $291 million in an initial public offering (IPO) on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share.

Who are Exscientia's major shareholders?

Exscientia's top institutional investors include Baillie Gifford & Co. (3.18%), Jane Street Group LLC (0.23%), Olympiad Research LP (0.08%) and Values First Advisors Inc. (0.05%).

How do I buy shares of Exscientia?

Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Exscientia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exscientia investors own include AUO (AUOTY), Waste Connections (WCN), American Water Works (AWK), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/20/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EXAI
• CUSIP: N/A
• CIK: 1865408
• Web: www.exscientia.ai
• Phone: 44-0-18-6581-8941
• Fax: N/A
• Employees: 280
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +44.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-181,560,000.00
• Net Margins: -882.09%
• Pretax Margin: -904.93%
• Return on Equity: -49.10%
• Return on Assets: -33.13%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 4.54
• Quick Ratio: 4.54

Sales & Book Value

• Annual Sales: $17.07 million
• Price / Sales: 37.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.66 per share
• Price / Book: 1.32

Miscellaneous

• Outstanding Shares: 130,770,000
• Free Float: N/A
• Market Cap: $632.93 million
• Optionable: Optionable
• Beta: 0.83